

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)
September 16, 2020

INTEC PHARMA LTD.
(Exact name of registrant as specified in its charter)

<u>Israel</u> (State or other jurisdiction of incorporation)	<u>001-37521</u> (Commission File Number)	<u>N/A</u> (IRS Employer Identification No.)
<u>12 Hartom St. Har Hotzvim Jerusalem, Israel</u> (Address of principal executive offices)		<u>9777512</u> (Zip Code)

+ 972-2 - 586-4657
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Ordinary Shares, no, par value	NTEC	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 16, 2020, the Board of Directors of Intec Pharma Ltd. (the “Company”), upon recommendation of its Compensation Committee, approved an executive retention award to each of Nir Sassi, the Company’s Chief Financial Officer and Walt A. Linscott, the Company’s Chief Business Officer, of 100,000 options to purchase ordinary shares of the Company pursuant to the Company’s 2015 Equity Incentive Plan. The foregoing options have an exercise price of \$0.3215 per share, have a seven-year term and, subject to the executive’s continued employment with the Company on the vesting date, vest on December 31, 2021.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 18, 2020

INTEC PHARMA LTD.

By: /s/ Nir Sassi

Nir Sassi
Chief Financial Officer